MDxHealth SA today provides a preliminary update on its year-end results, reporting that it expects to achieve its upgraded market guidance for full-year 2016 financial results following continued strong growth of ConfirmMDxA and early adoption of SelectMDx for Prostate Cancer during the year. The Company previously upgraded its expected full-year revenue growth to more than 60% compared with its initial guidance predicting growth of 30-50% over 2015.